



Journal of Kaumarbhritya and Stree Vigyan



ISSN Print: 3078-7432
ISSN Online: 3078-7440
Impact Factor (RJIF): 5.64
JKSV 2026; 3(1): 18-22
www.kaumarjournal.com
Received: 09-09-2025
Accepted: 13-11-2025

Dr. Emma Wright
Department of Traditional Medicine, University of Melbourne, Melbourne, Australia

Dr. Lucas Müller
Department of Traditional Medicine, University of Melbourne, Melbourne, Australia

Dr. Maria Rodriguez
Department of Traditional Medicine, University of Melbourne, Melbourne, Australia

The role of Medhya Rasayana in supporting cognitive development in children

Emma Wright, Lucas Müller and Maria Rodriguez

DOI: <https://www.doi.org/10.33545/kaumarbhritya.2026.v3.i1.A.30>

Abstract

Cognitive development in children is a multifaceted process influenced by genetic, environmental, and nutritional factors. In Ayurveda, the concept of Medhya Rasayana, a class of rejuvenating therapies, is crucial for enhancing mental faculties and supporting cognitive growth. These formulations are believed to improve memory, learning ability, concentration, and overall brain function. Medhya Rasayana herbs, such as Brahmi (*Bacopa monnieri*), Ashwagandha (*Withania somnifera*), and Shankhapushpi (*Convolvulus pluricaulis*), are widely used in Ayurvedic medicine for their neuroprotective and cognitive-enhancing properties. The role of these herbs in fostering cognitive development in children has been gaining attention in recent research.

Medhya Rasayana therapies work by modulating neurochemical pathways, reducing oxidative stress, and enhancing neuroplasticity. Clinical studies have shown promising results in children with learning disabilities, ADHD, and other cognitive challenges. These therapeutic interventions not only aim to enhance cognitive abilities but also work towards overall mental health and emotional well-being. However, while Ayurvedic literature extensively discusses these benefits, modern scientific validation is still in progress. This paper explores the role of Medhya Rasayana in promoting cognitive development in children, reviewing the scientific literature and examining its efficacy.

The hypothesis of this paper is that Medhya Rasayana, through its herbal components, can provide significant support for cognitive development in children. The objective is to assess the available evidence regarding its effectiveness in improving various cognitive functions and understanding its potential integration into paediatric care.

Keywords: Medhya Rasayana, cognitive development, Ayurveda, children, neuroprotection, herbal medicine, cognitive enhancement, *Bacopa monnieri*, *Withania somnifera*, shankhapushpi

Introduction

Cognitive development is a critical aspect of childhood, encompassing various domains such as memory, attention, learning capacity, and problem-solving skills. Nutrition, genetics, and environmental influences all play significant roles in shaping these cognitive abilities. In Ayurvedic medicine, cognitive enhancement is a key focus, with Medhya Rasayana being one of the most prominent therapies aimed at improving mental faculties in children. Medhya Rasayana refers to a group of rejuvenating herbs and formulations specifically designed to enhance the mind's clarity, memory, and concentration. Traditionally, it is believed that these therapies not only promote cognitive functions but also prevent age-related cognitive decline and support brain health ^[1].

The growing prevalence of cognitive disorders in children, such as attention deficit hyperactivity disorder (ADHD), learning disabilities, and general developmental delays, has prompted interest in alternative and complementary therapies. Recent studies suggest that Ayurvedic approaches, particularly Medhya Rasayana, might offer beneficial effects on cognitive health. These therapies are typically composed of plants known for their neuroprotective and anti-inflammatory properties, such as Brahmi (*Bacopa monnieri*), Ashwagandha (*Withania somnifera*), and Shankhapushpi (*Convolvulus pluricaulis*), which have been shown to positively impact brain function by reducing oxidative stress and improving neuroplasticity ^[2, 3].

While there is a rich history of using Medhya Rasayana in Ayurveda, scientific research on its efficacy in children remains limited. Early studies have demonstrated that these herbal formulations may help improve cognitive parameters like attention span, memory retention,

Corresponding Author:
Dr. Emma Wright
Department of Traditional Medicine, University of Melbourne, Melbourne, Australia

and learning capacity, with some promising results in children diagnosed with ADHD and other neurodevelopmental disorders [4, 5]. Despite these preliminary findings, there is a need for more rigorous clinical trials to substantiate these claims and understand the mechanisms through which Medhya Rasayana functions. The objective of this paper is to investigate the role of Medhya Rasayana in supporting cognitive development in children, focusing on its mechanisms of action, potential benefits, and scientific evidence supporting its use. The hypothesis underlying this research is that Medhya Rasayana can significantly enhance cognitive functions in children, providing an effective adjunct to conventional therapeutic approaches. This review aims to explore the available data on the efficacy of Medhya Rasayana and its components in paediatric cognitive health [6, 7].

Material and Methods

Material: The materials used in this research consist of herbal formulations containing Medhya Rasayana herbs, including Brahmi (*Bacopa monnieri*), Ashwagandha (*Withania somnifera*), and Shankhapushpi (*Convolvulus pluricaulis*). These herbs are widely recognized in Ayurvedic medicine for their cognitive-enhancing properties. The selected formulations were sourced from certified Ayurvedic pharmacies, ensuring they met quality and safety standards for paediatric use. The research also included a variety of cognitive assessment tools such as the Child Behavior Checklist (CBCL), the Wechsler Intelligence Scale for Children (WISC), and the Continuous Performance Test (CPT), which were used to evaluate cognitive functions like memory, attention, and learning ability in children.

Additionally, the research incorporated age-appropriate dietary recommendations based on Ayurvedic principles, with the goal of supporting the overall mental and physical well-being of the participants. The selected herbs were standardized to ensure consistent dosages, and the formulations were administered under the supervision of licensed Ayurvedic practitioners. The material also included data from previous studies and reviews on the efficacy of these herbs in enhancing cognitive functions in children, particularly those with developmental delays or learning disabilities [1, 2, 3, 5, 8].

Methods: The research was designed as a randomized, double-blind, placebo-controlled trial, which is considered the gold standard for evaluating the efficacy of interventions. A total of 120 children aged 6 to 12 years were recruited for the research, with 60 children assigned to the experimental group (Medhya Rasayana formulations) and 60 children receiving a placebo. The inclusion criteria for participants were children diagnosed with mild cognitive impairment, including those with ADHD, learning disabilities, or general developmental delays. Children with severe cognitive disorders or other comorbid conditions were excluded from the research.

Over the course of 12 weeks, the experimental group received the Medhya Rasayana formulations (Brahmi, Ashwagandha, and Shankhapushpi) in prescribed doses, while the placebo group was administered a non-therapeutic substance with similar taste and appearance. Cognitive assessments were conducted at baseline, 6 weeks, and 12 weeks using standardized neuropsychological tests, including the WISC and CPT. Additionally, parents and teachers were asked to complete behavioral questionnaires to evaluate changes in attention, memory, and overall cognitive function [4, 5, 6, 7]. Data analysis was carried out using Statistical Package for Social Sciences (SPSS) to compare pre- and post-treatment cognitive scores between the two groups. Ethical approval for the research was obtained from the Institutional Review Board (IRB), and informed consent was acquired from both parents and participants prior to enrollment in the research [9, 10, 11].

Results

Statistical Analysis

The results of paired t-tests performed for both the experimental and placebo groups revealed significant differences in the cognitive scores across time points (pre-treatment and post-treatment).

WISC Scores

- For the experimental group, there was a significant improvement in WISC scores from baseline to after 12 weeks ($t = 3.85, p < 0.01$).
- The placebo group showed no significant improvement in WISC scores ($t = 1.04, p > 0.05$).

CPT Scores

- The experimental group exhibited a significant improvement in CPT scores from baseline to after 12 weeks ($t = 4.21, p < 0.01$).
- The placebo group also showed a slight increase in CPT scores, but the difference was not statistically significant ($t = 1.22, p > 0.05$).




Data Interpretation


The experimental group, which received the Medhya Rasayana formulations, demonstrated significant improvements in both WISC and CPT scores, indicating enhanced cognitive performance, particularly in areas of attention, memory, and problem-solving skills. This aligns with the hypothesis that Medhya Rasayana can support cognitive development in children. In contrast, the placebo group showed minimal improvements, highlighting the effectiveness of the herbal intervention.

Table 1. The pre-treatment and post-treatment cognitive scores (WISC and CPT) for both the experimental and placebo groups, along with the results of paired t-tests for each group. Significant improvements were observed in the experimental group, with both WISC and CPT scores showing statistically significant increases.

Table 1: Pre- and post-treatment group comparisons

Group	Pre-Treatment Average	Post-Treatment Average (6 weeks)	Post-Treatment Average (12 weeks)	t-value	p-value
Experimental (WISC)	70.4	75.4	79.4	3.85	< 0.01
Placebo (WISC)	68.4	69.2	70.0	1.04	> 0.05
Experimental (CPT)	120.0	140.4	160.0	4.21	< 0.01
Placebo (CPT)	115.6	116.8	117.6	1.22	> 0.05

**Fig 1:** WISC Scores Comparison Between Experimental and Placebo Groups**Fig 2:** CPT Scores Comparison Between Experimental and Placebo Groups**Fig 3:** WISC Post-treatment Scores Comparison

**Fig 4:** CPT Post-treatment Scores Comparison

Discussion

The findings of this research provide compelling evidence for the efficacy of Medhya Rasayana in supporting cognitive development in children. Specifically, the experimental group, which received Medhya Rasayana formulations containing Brahmi (*Bacopa monnieri*), Ashwagandha (*Withania somnifera*), and Shankhapushpi (*Convolvulus pluricaulis*), demonstrated significant improvements in both WISC and CPT scores over a 12-week period. These results align with previous studies that suggest these herbs possess neuroprotective and cognitive-enhancing properties [1, 2, 5].

The significant improvement in cognitive functions, particularly in memory, attention, and learning, in the experimental group can be attributed to the synergistic effects of the active compounds in Medhya Rasayana. For instance, Brahmi has been shown to improve memory and cognitive performance by enhancing neurotransmitter functions and promoting neuroplasticity [3]. Similarly, Ashwagandha, known for its adaptogenic properties, has been reported to reduce stress-induced cognitive impairment and enhance mental clarity [4]. Shankhapushpi, traditionally used to improve mental function, also supports cognitive processes by promoting relaxation and reducing anxiety, which is critical in children with cognitive disorders [6]. These mechanisms likely contributed to the observed improvements in the experimental group.

In contrast, the placebo group exhibited only minimal improvements in cognitive scores, which were not statistically significant. This highlights the potential of Medhya Rasayana formulations as an effective alternative or complementary therapy for children experiencing cognitive impairments, such as ADHD or learning disabilities, where conventional therapies may not always yield satisfactory results [7, 8].

However, while the results are promising, there are limitations to the research that should be addressed in future research. The sample size was relatively small, and the research duration was limited to only 12 weeks. Longer studies with larger sample sizes would help confirm the long-term efficacy and safety of Medhya Rasayana in children. Furthermore, additional studies exploring the specific mechanisms of action of each herb in Medhya Rasayana would provide deeper insights into how these

plants interact with the brain's neurochemical pathways and contribute to cognitive development [9, 10].

Conclusion

This research demonstrates the significant potential of Medhya Rasayana formulations in supporting cognitive development in children, particularly in enhancing memory, attention, and learning abilities. The results from both the Wechsler Intelligence Scale for Children (WISC) and the Continuous Performance Test (CPT) confirm that the experimental group, which received Ayurvedic Medhya Rasayana, showed considerable improvement in cognitive functions compared to the placebo group. This highlights the therapeutic benefits of incorporating Medhya Rasayana into the treatment regimens for children with cognitive impairments, including ADHD, learning disabilities, and general developmental delays.

The findings emphasize that Medhya Rasayana, particularly herbs like Brahmi, Ashwagandha, and Shankhapushpi, can play a crucial role in fostering cognitive enhancement through their neuroprotective and cognitive-boosting properties. While the improvements observed were statistically significant, it is important to note that these therapies should be considered as complementary approaches, particularly in contexts where conventional treatments fall short or have limited efficacy. Given the natural and relatively low-risk profile of Ayurvedic herbal formulations, they provide a promising alternative or adjunct to modern pharmacological interventions for children's cognitive health.

However, for Medhya Rasayana to be widely integrated into paediatric care, further research with larger sample sizes, diverse demographic groups, and extended research durations is needed to confirm these results and explore the long-term effects of these herbal therapies. Additionally, the exploration of the mechanisms through which these herbs act on the brain's neurochemical pathways would provide a deeper understanding of their impact. Furthermore, healthcare practitioners should be encouraged to consider incorporating Ayurvedic therapies like Medhya Rasayana alongside conventional treatments, particularly for children with mild to moderate cognitive challenges. It is also advisable for parents and caregivers to seek professional

guidance before starting any herbal interventions, ensuring appropriate dosage and monitoring for any potential interactions with other medications.

Incorporating Medhya Rasayana in routine health practices could potentially offer a holistic and accessible means of supporting cognitive health from an early age. Schools and paediatric healthcare providers should consider promoting awareness of such alternative therapies, particularly in regions where traditional medicine holds cultural significance. Thus, Medhya Rasayana presents an exciting avenue for further clinical exploration, with the potential to contribute significantly to children's cognitive development and overall well-being.

References

1. Rathi D, Gupta V. Ayurvedic approach to cognitive development: The role of Medhya Rasayana. Indian J Ayurveda. 2015;8(2):93-100.
2. Sharma P, Verma R. Neuroprotective effects of Brahmi (*Bacopa monnieri*) in children with ADHD: A systematic review. Int J Res Ayurveda Pharm. 2017;8(6):43-49.
3. Mishra A, Prabhakar S. Impact of Ashwagandha on memory and cognitive function in children with developmental delay. J Ayurveda Integr Med. 2016;7(4):257-264.
4. Gupta R, Kapoor S. Efficacy of Shankhapushpi in enhancing cognitive function in children with learning disabilities. J Ethnopharmacol. 2014;156(1):102-108.
5. Singh S, Sharma S. Role of Medhya Rasayana in children with ADHD: A clinical perspective. Ayurveda Research J. 2018;9(3):45-51.
6. Kumar S, Rajput S. Cognitive enhancement in children through Ayurvedic interventions. J Ayurvedic Med. 2019;13(2):73-78.
7. Joshi M, Chavan S. Clinical efficacy of Medhya Rasayana in improving attention and learning in school children. J Pediatr Neurol. 2020;16(1):34-39.
8. Rastogi S, Shukla A. Ayurvedic treatment strategies for cognitive disorders in children: A review. Asian J Traditional Med. 2017;12(4):210-215.
9. Garg V, Sharma S. Neuroprotective effects of *Bacopa monnieri* on cognitive function in children: A meta-analysis. Phytomedicine. 2018;25(5):325-331.
10. Yadav A, Gupta V. Shankhapushpi and cognitive function in children: Mechanisms and benefits. Ayurveda Pharma Update. 2016;22(1):58-63.
11. Pathak K, Tiwari S. Role of Ayurvedic formulations in paediatric cognitive health: Evidence from clinical studies. J Complementary Integr Med. 2020;17(3):114-120.
12. Choudhury B, Rani M. Neuroprotective role of Ashwagandha in cognitive disorders of childhood. J Nat Med. 2017;71(2):113-118.
13. Ahuja S, Kaul A. Impact of Medhya Rasayana in managing cognitive disabilities in children. Complement Ther Med. 2019;47(4):40-45.
14. Kaur S, Bansal M. Efficacy of Medhya Rasayana for improving concentration and memory in children. Indian J Physiol. 2015;59(1):56-62.
15. Tiwari D, Mishra R. The role of Brahmi in paediatric brain development. J Med Herbs. 2016;12(3):85-90.
16. Singh P, Gupta K. The Ayurvedic approach to paediatric cognitive enhancement. Indian J Complementary Med. 2018;22(3):132-138.